TT Electronics Minneapolis Facility Secures FDA Registration

TT Electronics, a global provider of engineered technologies for performance critical applications, today announced the receipt of U.S. Federal Drug Administration (FDA) registration for its Minneapolis, Minnesota manufacturing facility. Securing this registration allows the company to manufacture finished instruments and devices such as imaging, diagnostic and therapeutic equipment for the healthcare market, in the USA.

Now as an FDA registered location, the facility is recognised by and subject to the rigorous standards of the FDA, further reinforcing the company’s commitment to supporting its global customers with a wide range of high-reliability products and services across key highly regulated end markets. This development also builds on FDA registration received last year by the TT Cleveland facility which has paved the way for increasing collaboration between the two locations to further support our medical customers with complete, vertically integrated solutions by utilising the complimentary capabilities of our teams and sites in Ohio and Minnesota respectively. These registrations and this enhanced value offering further demonstrate the steps TT is actively taking to better respond to the increased demand seen in the medical and life science domain.

“This latest milestone demonstrates our commitment to the healthcare industry and the momentum behind our growth strategy. FDA designation is not easily awarded and will provide a significant advantage in supporting our current customer base, many of whom are global leaders in their fields. TT has long been a partner for medical device and life science technology innovators and we’re proud to continue securing milestones like this one to support our customers with an enhanced ability to leverage our growing capabilities in the USA. Our increasing expertise and track record in manufacturing and delivering finished, complex medical products – still founded on world-class service is a compelling offering which we’re delighted to provide to our partners,” said TT Electronics Power Solutions VP/GM, Matt Sweaney.

Manufacturing facilities involved in the production and distribution of medical devices intended for use in the United States healthcare sector are required to register annually with the FDA. This registration provides the FDA with the location of medical device establishments and the devices manufactured at those establishments. Knowing where devices are made increases the nation’s ability to prepare for and respond to public health emergencies such as those experienced in recent years in responding to the coronavirus pandemic.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”